Pitolisant hydrochloride

For research use only. Not for therapeutic Use.

  • CAT Number: I005406
  • CAS Number: 903576-44-3
  • Molecular Formula: C17H26ClNO ? HCl
  • Molecular Weight: 332.30
  • Purity: 98%
Inquiry Now

Pitolisant hydrochloride(Cat No.: I005406) is a medication used for the treatment of narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. It works by selectively blocking the histamine H3 receptor, which is involved in regulating wakefulness and sleep. By blocking this receptor, pitolisant increases the levels of histamine and other wake-promoting neurotransmitters in the brain, leading to improved wakefulness and reduced daytime sleepiness. Pitolisant hydrochloride has been shown to be effective and well-tolerated in clinical trials, and is currently approved for use in several countries, including the European Union and the United States.


Catalog Number I005406
CAS Number 903576-44-3
Synonyms

1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride

Molecular Formula C17H26ClNO ? HCl
Purity 98%
Target H3 receptor
Target Protein

Q9Y5N1

Solubility DMSO: ≥ 43 mg/mL
Appearance Solid
Storage Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
Related CAS 362665-56-3(free base)    
Overview of Clinical Research

Pitolisant hydrochloride has been granted orphan drug status in the EU and US. It is currently in clinical trials for schizophrenia and Parkinson/'s disease.

IC50 Ki: 0.16 nM (H3 receptor)
IUPAC Name 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine;hydrochloride
InChI InChI=1S/C17H26ClNO.ClH/c18-17-9-7-16(8-10-17)6-4-14-20-15-5-13-19-11-2-1-3-12-19;/h7-10H,1-6,11-15H2;1H
InChIKey XLFKECRRMPOAQS-UHFFFAOYSA-N
SMILES C1CCN(CC1)CCCOCCCC2=CC=C(C=C2)Cl.Cl
Reference

1. Nat Sci Sleep. 2017 Apr 26;9:127-133. doi: 10.2147/NSS.S103462. eCollection 2017.<br />
<br />
Update on the treatment of narcolepsy: clinical efficacy of pitolisant.<br />
<br />
Calik MW(1)(2).<br />
Author information:<br />
(1)Department of Biobehavioral Health Science. (2)Center for Narcolepsy, Sleep and Health Research, University of Illinois at Chicago, Chicago, IL, United States.<br />
Narcolepsy is a neurological disease that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness (EDS). In 60-70% of individuals with narcolepsy, it is also characterized by cataplexy or a sudden loss of muscle tone that is triggered by positive or negative emotions. Narcolepsy decreases the quality of life of the afflicted individuals. Currently used drugs treat EDS alone (modafinil/armodafinil, methylphenidate, and amphetamine), cataplexy alone (/off-label/ use of antidepressants), or both EDS and cataplexy (sodium oxybate). These drugs have abuse, tolerability, and adherence issues. A greater diversity of drug options is needed to treat narcolepsy. The small molecule drug, pitolisant, acts as an inverse agonist/antagonist at the H3 receptor, thus increasing histaminergic tone in the wake promoting system of the brain. Pitolisant has been studied in animal models of narcolepsy and used in clinical trials as a treatment for narcolepsy. A comprehensive search of online databases (eg, Medline, PubMed, EMBASE, the Cochrane Library Database, Ovid MEDLINE, Europe PubMed Central, EBSCOhost CINAHL, ProQuest Research Library, Google Scholar, and ClinicalTrials.gov) was performed. Nonrandomized and randomized studies were included. This review focuses on the outcomes of four clinical trials of pitolisant to treat narcolepsy. These four trials show that pitolisant is an effective drug to treat EDS and cataplexy in narcolepsy.<br />
<br />
2. Br J Pharmacol. 2011 Jun;163(4):713-21. doi: 10.1111/j.1476-5381.2011.01286.x.<br />
<br />
The histamine H3 receptor: from discovery to clinical trials with pitolisant.<br />
<br />
Schwartz JC(1).<br />
Author information:<br />
(1)Centre de recherche, Bioprojet-Biotech, Saint Gregoire Cedex, France. [email protected]<br />
The third histamine receptor was discovered in 1983 by a traditional pharmacological approach, consisting of assessing the inhibitory effect of histamine on its own release from depolarized rat brain slices. The same in vitro test was used to design, in 1987, the first highly selective and potent H3-autoreceptor ligands, the antagonist thioperamide and the agonist (R)alphamethylhistamine which enhances and inhibits, respectively, the activity of histaminergic neurons in brain. The use of these research tools was instrumental in establishing the main functions of cerebral histaminergic neurons, namely their role in maintenance of wakefulness, attention, learning and other cognitive processes. In 1990, the cloning of the gene of the H3-receptor, a member of the superfamily of heptahelical receptors coupled to G proteins, paved the way to the demonstration of the high constitutive activity of the receptor, including its native form, and its participation in the tonic control of histamine release; it also facilitated the development of H3-receptor inverse agonist programs in many drug companies. Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride) is the first inverse agonist to be introduced in the clinics. Its wake-promotion activity was evidenced in excessive diurnal sleepiness of patients with narcolepsy, Parkinson/&#39;s disease or Obstructive Sleep Apnea/Hypopnea, in which this activity is characterized by a mean decrease of the Epworth Sleepiness Scale by about five units. The procognitive activity of this novel class of drugs may also find therapeutic applications in dementias, schizophrenia or attention deficit hyperactivity disorder.<br />

Request a Quote